Clinical TrialsCAMP announced a clean safety profile from four SAD cohorts in the Ph1 trial of CMP-CPS-001, with ongoing progress in urea cycle disorders.
Financial PerformanceCAMP ended the quarter with $64.0 million in cash and equivalents, indicating strong liquidity.
Market OpportunityCMP-CPS-001 has a larger total addressable market and meets a high unmet need in urea cycle disorders, which presents an upside risk and reward opportunity.